Megestrol for weight loss in small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a drug called megestrol acetate, which is a type of progesterone that can help increase appetite and reduce weight loss. It is for people with a certain type of lung cancer (small cell lung cancer) that has spread, especially if they are experiencing early signs of weight loss or frailty.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have small cell lung cancer that has spread (extensive stage).
- You must have at least one tumor that can be measured on imaging scans.
- You must show signs of weight loss (pre-cachexia or cachexia).
- You must not have had chemotherapy for metastatic disease before, although some prior treatments are allowed if the cancer came back more than 6 months later.
- You must not have untreated or active brain metastases, uncontrolled pain, or significant heart or blood vessel problems.
- You must be able to take medicine by mouth and not have other conditions that might interfere with the drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a drug that boosts appetite and weight to standard lung cancer treatment helps people with advanced small cell lung cancer who are experiencing weight loss and poor appetite. It aims to improve quality of life and treatment outcomes.
This trial tests whether adding a drug called nanocrystalline megestrol to standard chemotherapy and immunotherapy can help patients with extensive-stage small cell lung cancer who are losing weight or have poor appetite. It aims to improve nutrition and overall well-being during treatment.
This trial tests a drug called megestrol acetate to help people with advanced lung cancer who are losing weight or have poor appetite. It aims to improve nutrition and quality of life.
This study tests a new form of megestrol, a medicine that helps stimulate appetite and promote weight gain, in people with advanced non-small cell lung cancer who are starting their first chemotherapy and are at risk of malnutrition. The goal is to see if it improves nutrition and overall well-being during treatment.
This study tests a medicine called nanocrystalline megestrol acetate to see if it can help improve appetite and promote weight gain in people with advanced non-small cell lung cancer who are losing weight. If you qualify, you would receive this treatment alongside your regular care to help you feel better and maintain your strength.
This study is testing whether a medication called megestrol acetate (a type of hormone that can boost appetite and help with weight gain) can improve outcomes for people with advanced non-small cell lung cancer who are malnourished. It is used as part of first-line treatment, meaning before any chemotherapy for the advanced cancer.
Hear when a new Extensive-stage Small Cell Lung Cancer (ES-SCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.